Why muscle preservation?
The name is ambitious. Retaining useful capacity gives that ambition a concrete subject.
An appetite for function
An age-defying claim earns my patience only when it says what a body can do. The MOTS-c experiments involving muscle atrophy and CK2 give the phrase a problem I can understand: preserving tissue through a challenge. The NMN result in prediabetic, postmenopausal women gives it a human metabolic finding with some conspicuous measures left unchanged.
Selective results suit my temperament better. A molecule can affect one response while leaving another alone; a result can be compelling in mice while its human value remains open. The specificity feels more useful than the broad adjective “rejuvenating.”
AgeDefy Peptide is a personal publication through which I explore the published research on NAD+ and MOTS-c. The pleasure is in the biology and the argument it provokes. Nothing here is medical advice, and these articles cannot judge which treatment fits a particular person.
Human functional outcomes
“Defy” suggests resistance. For me, the worthwhile question is resistance to losing function: whether muscle can retain its capacity, and whether a metabolic change has consequences that last. The studies here approach that question through different systems, from immobilized mice to a controlled NMN trial.
The 2025 synthesis of NAD+ precursor trials leaves plenty unresolved. Limited human clinical efficacy and sparse tissue-specific measurements make a sweeping verdict premature. For now, I’m waiting for sustained functional benefits in people before going further.
The unresolved issue is the durability of an effect after the first encouraging measurement. A metabolic change gains practical weight when its functional consequences persist. Animal performance, human muscle insulin sensitivity and circulating biomarkers each deserve to retain the conditions that gave them meaning.
Clinical decisions
AgeDefy Peptide offers articles, not appointments or products. A reader’s symptoms, personal test results and treatment plans require clinical assessment beyond these articles. Those decisions require a licensed clinician who can review the individual case.
The references contain the literature discussed here. A correction that changes the biological argument is welcome, especially if it restores an overlooked population, experimental condition or outcome. The contact page gives the editorial address and the information that makes a correction usable.